📃 Paper Title: Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects
🧍 Author: Cristóbal Ramírez Sevilla
🕒 Year: 2019
📚 Journal: BMC Infectious Diseases
🌎 Country: Spain
ㅤContext to the study:
Can you cite a paper evaluating the efficacy of uromune vaccine in management of recurrent UTIs?
ㅤ✅ Take-home message of study:
Uromune, a bacterial vaccine, is an effective alternative to antibiotics for the prevention of uncomplicated recurrent urinary tract infections. Sublingual spray of Uromune (administered daily for 03-months) reduced the number of UTI episodes to ≤1 in 71.7% and ≤1 in 64.7%.of patients, when checked at three months and six months respectively after stopping the drug.
ㅤ Descriptive Prospective (Observational) Study
ㅤ
Study participants:
Number of subjects (N) = 784;
Gender Distribution:
Females 82.7% (n=648): Pre-menopausal - 5.7% (n=37); Post-menopausal - 94.3% (n=611)
Males 17.3% (136) males
Mean age: 73.5 years ±12.75 (range 19-97)
ㅤ
ㅤ
Key study outcomes:
Uromune reduced the number of episodes to zero or one in 71.7% and 64.7% at three and six months with minimal side effects.
The sub-population of women over 50 years old showed the most benefit. 74.5% and 66.5% of post-menopausal women observed a reduction in episodes of UTIs to ≤1 when assessed at 3 and 6 months respectively.
Immunoprophylaxis with sublingual uromune has been recommended as the treatment of first choice for prevention of uncomplicated recurrent urinary tract infections.
Use of uromune can reduce the consumption of antibiotics, while preventing an increase in bacterial resistance.
ㅤ
ㅤ
Study Limitations:
The study consisted pre-dominantly of post-menopausal females (77.9%, n=611), in whom the drug showed significant positive effects. However, in order to provide stronger evidence of similar effects in pre-menopausal females and males, studies focusing exclusively on these population groups need to be conducted.
The study is not comparative, and a case-control study design would have provided stronger evidence.
The study did not include people with long-term catheters or nephrostomies, considering that they are at a higher risk for recurrent UTIs.
ㅤ